Abcam plc (AIM: ABC; Nasdaq: ABCM) (“
Abcam”), a
global leader in the supply of life science research tools, is
delighted to announce the appointments of Bessie Lee and Mark
Capone as non-executive Directors with immediate effect.
Both Bessie and Mark bring extensive and
complementary executive and non-executive experience to the Board
of Abcam.
Based in China, Bessie Lee is the Chief
Executive Officer of Withinlink, a China-based venture capital firm
and start-up incubator focused on marketing technology, which she
founded in 2015. Prior to founding Withinlink, Bessie spent almost
three decades at WPP plc, holding Chief Executive Officer roles in
China for Mindshare, GroupM and finally WPP. Bessie is currently a
non-executive Director of Electrocomponents plc, Homeplus Digital
Co Ltd and Shanghai Fuge Information Technology Co Ltd. She also
acts as an Advisor to Didi Chuxing and Greater Pacific Capital.
Based in the US, Mark Capone is an accomplished
life sciences executive with more than 35 years’ experience. He
spent over 17 years with Myriad Genetics, latterly as Chief
Executive Officer and President, over which time he grew the
company into a leading global precision medicine company. Prior to
joining Myriad Genetics, Mark spent 17 years with Eli Lilly and
Company in positions across the entire value chain. Mark is
currently the Chief Executive Officer of Precision Medicine
Advisors, a consultancy for molecular diagnostics, pharmaceuticals
and biotechnology organizations, which he founded in 2020.
Peter Allen, Chairman of Abcam
said: "I am delighted to welcome Bessie and Mark to the Board of
Abcam. Bessie brings deep insight into customer and digital
marketing dynamics in China, one of our key strategic markets,
whilst Mark brings a wealth of experience within the life science
sector and a first-hand understanding of our diagnostic and
biopharma customers. Their expertise will be invaluable as we
continue to work towards our long-term growth plans.”
Mark Capone will join the Remuneration
Committee.
The composition of each of the Board Committees
is confirmed as follows:
Board Committee |
Membership |
Nomination Committee |
Peter Allen (Chairman)Louise PattenMara AspinallGiles Kerr |
Remuneration Committee |
Louise Patten (Chairman)Peter AllenMara AspinallGiles KerrMark
Capone |
Audit and Risk Committee |
Giles Kerr (Chairman)Louise PattenMara Aspinall |
AIM Rules disclosures
Bessie Chien Ling Lee (age 55) holds or has held directorships
in the five years preceding her appointment at Abcam as
follows:
Current Directorships |
Previous Directorships |
Withinlink (Shanghai) Investment Management Co Ltd |
Beixi (Shanghai) Trading Co Ltd |
Electrocomponents plc |
Shanghai Kuvera Ecommerce Co Ltd |
Homeplus Digital Co Ltd (formerly China Networks Systems Co
Ltd) |
Weitewei Internet Technology (Shanghai) Co Ltd |
Shanghai Fuge Information Technology Co Ltd |
Dabang (Shanghai) Management Co Ltd |
|
Kinetic Advertising (Shanghai) Co Ltd |
|
GROWWW Communications Group (formerly United Communications
Group) |
|
Ecovacs Robotics Co Ltd |
|
GROWWW Media Co Ltd |
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
Mark Christopher Capone (age 58) holds or has held directorships
in the five years preceding his appointment at Abcam as
follows:
Current Directorships |
Previous Directorships |
Precision Medicine Advisors LLC |
Myriad Genetics Inc |
|
Myriad RMB |
|
Myriad Genetics Laboratories Inc |
|
Crescendo Bioscience Inc |
|
American Clinical Laboratory Association |
|
Coalition for 21st Century Medicine |
|
Assurex Health, Inc |
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
For further information, please contact:
Abcam+ 44 (0) 1223 696 000Marc
Perkins, Company SecretaryJames Staveley, VP, Investor
Relations
Numis - Nominated Advisor & Joint
Corporate Broker+ 44 (0) 20 7260 1000Garry Levin / Duncan
Monteith / Huw Jeremy
J.P.Morgan Cazenove - Joint Corporate
Broker+44 (0) 20 7742 4000James Mitford / Hemant
Kapoor
Morgan Stanley – Joint Corporate
Broker+ 44 (0) 207 425 8000Tom Perry / Luka Kezic
FTI Consulting+ 44 (0) 20 3727
1000Ben Atwell / Natalie Garland-Collins
About Abcam plcAs an innovator
in reagents and tools, Abcam's purpose is to serve life science
researchers globally to achieve their mission, faster. Providing
the research and clinical communities with tools and scientific
support, the Company offers highly validated antibodies, assays and
other research tools to address important targets in critical
biological pathways.
Already a pioneer in data sharing and ecommerce
in the life sciences, Abcam's ambition is to be the most
influential company in life sciences by helping advance global
understanding of biology and causes of disease, which, in turn,
will drive new treatments and improved health.
Abcam's worldwide customer base of approximately
750,000 life science researchers uses Abcam's antibodies, reagents,
biomarkers and assays. By actively listening to and collaborating
with these researchers, the Company continuously advances its
portfolio to address their needs. A transparent programme of
customer reviews and datasheets, combined with an industry-leading
validation initiative, gives researchers increased confidence in
their results.
Founded in 1998 and headquartered in Cambridge,
UK, the Company has served customers in more than 130 countries.
Abcam’s ordinary shares are listed on the London Stock Exchange
(AIM: ABC) and its American Depositary Shares (ADSs) trade on the
Nasdaq Global Market (Nasdaq: ABCM).
For more information, please
visit www.abcam.com or www.abcamplc.com
Forward-Looking Statements
This announcement contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Any express or implied statements contained in
this announcement that are not statements of historical fact may be
deemed to be forward-looking statements, including, without
limitation, statements regarding Abcam's portfolio and ambitions,
expected performance for first half 2021, as well as statements
that include the words “expect,” “intend,” “plan,” “believe,”
“project,” “forecast,” “estimate,” “may,” “should,” “anticipate”
and similar statements of a future or forward-looking nature.
Forward-looking statements are neither promises nor
guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation: a regional or
global health pandemic, including the novel coronavirus
(“COVID-19”), which has adversely affected elements of our
business, could severely affect our business, including due to
impacts on our operations and supply chains; challenges in
implementing our strategies for revenue growth in light of
competitive challenges; developing new products and enhancing
existing products, adapting to significant technological change and
responding to the introduction of new products by competitors to
remain competitive; failing to successfully identify or integrate
acquired businesses or assets into our operations or fully
recognize the anticipated benefits of businesses or assets that we
acquire; if our customers discontinue or spend less on research,
development, production or other scientific endeavours; failing to
successfully use, access and maintain information systems and
implement new systems to handle our changing needs; cyber security
risks and any failure to maintain the confidentiality, integrity
and availability of our computer hardware, software and internet
applications and related tools and functions; failing to
successfully manage our current and potential future growth; any
significant interruptions in our operations; if our products fail
to satisfy applicable quality criteria, specifications and
performance standards; failing to maintain our brand and
reputation; our dependence upon management and highly skilled
employees and our ability to attract and retain these highly
skilled employees; and the important factors discussed under the
caption “Risk Factors” in Abcam's prospectus pursuant to Rule
424(b) filed with the U.S. Securities and Exchange Commission
(“SEC”) on 22 October 2020, which is on file with the SEC and is
available on the SEC website at www.sec.gov, as such factors may be
updated from time to time in Abcam's other filings with the SEC.
Any forward-looking statements contained in this announcement speak
only as of the date hereof and accordingly undue reliance should
not be placed on such statements. Abcam disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this announcement, whether as a result of new
information, future events or otherwise, other than to the extent
required by applicable law.
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From May 2023 to May 2024